Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| PHOE | Phoenix Asia | $26.00 | -$107.12 | -80.47% | 97K | $2.9B | $2.31$133.12 |
| ATOS | Atossa Therapeutics | $6.40 | -$2.08 | -24.48% | 236.5K | $1.1B | $6.17$19.35 |
| DFLI | Dragonfly Energy | $2.44 | -$0.76 | -23.75% | 879.1K | $39M | $1.50$26.10 |
| BUUU | Buuu Group | $8.80 | -$2.69 | -23.41% | 25.4K | $192M | $3.67$20.76 |
| BTOG | Bit Origin | $3.20 | -$0.85 | -20.92% | 144.8K | $9.1M | $2.58$60.60 |
| WHLR | Wheeler Real Estate Investment Trust | $3.80 | -$0.96 | -20.17% | 64.6K | $3.3M | $3.76$6,793.50 |
| SOLT | Volatility Shares Trust - 2x Solana ETF | $4.34 | -$1.07 | -19.78% | 7M | - | $4.14$35.30 |
| ANL | Adlai Nortye | $8.53 | -$2.10 | -19.75% | 369K | $332M | $0.88$11.05 |
| XPEG | Themes ETF Trust - Leverage Shares 2x Long Xpev Daily ETF | $9.12 | -$2.19 | -19.34% | 13.8K | - | $9.06$15.89 |
| YEXT | Yext | $5.82 | -$1.34 | -18.71% | 48.5K | $878M | $5.51$9.20 |
| TXXS | Listed Funds Trust - 21Shares 2x Long Sui ETF | $9.24 | -$2.11 | -18.58% | 22.7K | - | $9.00$30.70 |
| VIVS | VivoSim Labs | $2.42 | -$0.50 | -17.27% | 876.2K | $7.6M | $1.41$21.96 |
| VTIX | Virtuix | $5.59 | -$1.13 | -16.82% | 299K | $207M | $5.26$92.74 |
| HODU | Direxion Shares ETF Trust - Direxion Daily Hood Bull 2x ETF | $14.11 | -$2.84 | -16.75% | 24.1K | - | $13.70$35.58 |
| HOOX | Tidal Trust II - Defiance Daily Target 2x Long Hood ETF | $12.95 | -$2.46 | -15.96% | 190.5K | - | $2.26$45.53 |
| HOOG | Themes ETF Trust - Leverage Shares 2x Long Hood Daily ETF | $34.16 | -$6.44 | -15.86% | 220.7K | - | $6.88$132.19 |
| PHAR | Pharming Group | $17.30 | -$3.17 | -15.49% | 72.7K | $1.4B | $7.50$21.34 |
| IOTR | iOThree | $3.84 | -$0.57 | -12.93% | 48.5K | $11M | $2.24$59.80 |
Related Articles
Featured Article
Can Atossa Therapeutics Stock Keep Climbing?
Cory Renauer|Jun 28, 2021
Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.
2 Stocks I Bought Last Week, and 1 Stock I Sold
Rick Munarriz|Nov 11, 2020
This Fool bought into a fast-growing sports-first streaming service and a disruptive mattress maker. He also sold a tech stock cashing in on the credibility gap of online search.
3 Technology Stocks I'd Buy Right Now
Jon Quast|Apr 29, 2020
Don't let current economic uncertainty keep you away from these companies with long-term potential.
My Top Growth Stock for 2020
Simon Erickson|Jan 5, 2020
After seven years of New Year's recommendations, my average pick is up 112%. See which growth-style investment I'm tapping next.
Why Zoom Video Communications, PagerDuty, and Yext Slumped Today
Dan Caplinger|Dec 6, 2019
Even on a strong day on Wall Street, poor earnings held some stocks back.
Where Will Organovo Holdings, Inc. Be in 5 Years?
Cory Renauer|Dec 3, 2017
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Why Tiny Organovo Is Giving Money to Huge Biotech Amgen
Keith Speights|Aug 30, 2017
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
Keith Speights|Aug 10, 2017
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
How Risky Is Organovo Holdings, Inc.?
Keith Speights|Jul 18, 2017
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More
Keith Speights|Jun 22, 2017
Could the beaten-down 3D bioprinting stock face even worse days ahead?
